Skip to main content

C. Difficile Infection

Contact Us Regarding Out-licensing

Clostridioides difficile infection (CDI or C. diff.) is an insidious disease which can be debilitating, characterized by watery diarrhea and abdominal cramping and may be accompanied by nausea, fever, and dehydration.1 C. diff. can also result in more serious disease complications, including bowel perforation (a tear in the gastrointestinal tract), sepsis, and potentially death. It necessitates patient isolation because of its highly contagious nature, making it able to be passed from one person to another either in a hospital or long-term care facility setting, as well as in the community.1

C. diff is a bacteria that produces toxins causing inflammation of the colon.1 Antibiotic exposure, especially broad-spectrum agents, disrupts the gut microbiota and is a major risk factor for disease.2,3 Recurrent CDI remains a major issue after an initial episode, with the likelihood of recurrence increasing with each subsequent infection. 2,3

Ridinilazole is an investigational therapy that is being studied for the treatment of and the reduction of recurrence of C. difficile infection. Ridinilazole is not approved by any regulatory authority, and commercialization of ridinilazole is subject to regulatory approvals.

To inquire further, please contact Dave Gancarz: bd@smmttx.com

Est. 500,000

Cases per year in the US3

Est. $5.4 billion

Annual acute care costs, 20,000 – 30,000 deaths per year in the US3

20% – 35% recurrence in patients

Recurrence is a primary clinical issue in CDI, as up to 20% – 35% of initial cases of CDI result in a second episode; the risk of recurrence rises to 60% after a third episode3

Urgent Threat

The highest threat designation by US CDC; C. difficile is one of only four bacteria to carry that label, requiring immediate, aggressive action3,4

References

  1. C. difficile infection. Mayo Clinic. (2023). Accessed Nov 28, 2023. (v0.1).
  2. Song, JH, et al. Gut and Liver 2019;13(1):16-24 (v0.1).
  3. Feuerstadt, P, et al. BMC Infect Dis. 2023;23 (v0.1).
  4. 2019 AR Threats Report. CDC. (v0.1).
Sign Up for Updates

For further information on how we protect your information, please refer to our Privacy Policy.

*Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).

© Summit Therapeutics Inc.

Trademarks, Registered or Otherwise, are the property of their respective owner(s).